The pharmaceutical group Salvat surpasses €100 million in revenue for the first time

In 2025, the pharmaceutical group Salvat surpassed the 100 million euro mark in net revenue for the first time, with a growth of 10.3% compared to the previous year, and a net operating profit (EBITDA) of 17.2 million, 25% more.